Appointment of three internal senior executives ensures strategic continuity with a new era of leadership

任命三位内部高级管理人员，确保了战略的连续性，开启了领导的新时代。

Jean-Charles Wirth to become CEO Life Science, succeeding Matthias Heinzel, who has decided to not renew his contract

让-查尔斯·维尔特将接替马蒂亚斯·海因策尔成为生命科学部门的首席执行官，后者决定不再续签合同。

Danny Bar-Zohar to become CEO Healthcare, succeeding Peter Guenter, who has decided to retire from Merck

丹尼·巴尔-佐哈尔将接替彼得·冈特成为默克公司医疗保健部门的首席执行官，彼得·冈特已决定从默克退休。

Khadija Ben Hammada joins Executive Board in newly created role as Chief People Officer

Khadija Ben Hammada 加入执行董事会，担任新设立的首席人力官职位。

Darmstadt, Germany, February 18, 2025 – The Board of Partners of E. Merck KG has appointed three new members to the Executive Board of Merck KGaA – a natural evolution in the company’s leadership as it continues to implement its growth strategy.

德国达姆施塔特，2025年2月18日 —— E. Merck KG 合伙人董事会任命了三位新成员加入默克集团（Merck KGaA）执行董事会，这是公司持续推进其增长战略过程中领导层的自然更替。

Jean-Charles Wirth (51), who currently heads Science & Lab Solutions within Merck's Life Science business sector, will become CEO Life Science as of June 1, 2025. He succeeds Matthias Heinzel (58), who has successfully set the Life Science business sector on a sustainable growth path during the extremely challenging phases of the pandemic.

让-查尔斯·维尔特（51岁），目前负责默克生命科学业务领域的科学与实验室解决方案部门，将于2025年6月1日接任生命科学首席执行官一职。他接替了马蒂亚斯·海因策尔（58岁），后者在疫情期间极为艰难的阶段成功带领生命科学业务领域走上可持续增长的道路。

He has decided to not renew his contract with the company to serve on the boards of public companies and to pursue his interest in private equity..

他已决定不与公司续签合同，以便在上市公司董事会任职，并追求他在私募股权方面的兴趣。

Danny Bar-Zohar (54), currently Global Head of Research & Development and Chief Medical Officer of the Healthcare business sector, will take on the position of CEO Healthcare, as of June 1, 2025. He succeeds Peter Guenter (62) who has decided to retire from Merck after a successful career spanning almost 40 years in the pharmaceutical industry.

丹尼·巴尔·佐哈尔（54岁），目前担任医疗保健业务领域的全球研发主管兼首席医疗官，将于2025年6月1日起接任医疗保健首席执行官一职。他接替彼得·古恩特（62岁），后者在制药行业成功工作近40年后决定从默克公司退休。

Peter Guenter will continue to serve on the boards of public companies and pursue further opportunities in private equity..

彼得·根特将继续在上市公司董事会任职，并在私募股权领域寻求更多机会。

Jean-Charles Wirth and Danny Bar-Zohar will have a 90-day transition with their predecessors to ensure a seamless handover for Merck’s global businesses.

让-查尔斯·维尔特和丹尼·巴尔-佐哈尔将与他们的前任进行为期90天的过渡，以确保默克全球业务的无缝交接。

Khadija Ben Hammada (44), Merck’s Chief Human Resources Officer, will join the Executive Board in the newly created role of Chief People Officer as of March 1, 2025. She will also be responsible for Corporate Sustainability, Quality & Trade Compliance, Inhouse Consulting, as well as Site Management of the company headquarters in Darmstadt, Germany.

Khadija Ben Hammada（44岁），默克公司首席人力资源官，将于2025年3月1日起加入执行董事会，担任新设立的首席人事官一职。她还将负责企业可持续发展、质量与贸易合规、内部咨询，以及德国达姆施塔特公司总部的场地管理。

Her appointment to the Executive Board – which increases the board to six people – illustrates the relevance of people and talent for the long-term growth, resilience and sustained success of Merck..

她被任命为执行董事会成员（这使得董事会成员增至六人）表明了人员和人才对默克公司长期增长、弹性和持续成功的重要性。

“We would like to express our heartfelt thanks to Matthias Heinzel and Peter Guenter for their years of service to our company. Matthias Heinzel successfully steered the Life Science business sector while resetting its strategy and operating model, implementing a strong senior leadership team and setting the business on a sustainable growth path.

“我们要向马蒂亚斯·海因策尔和彼得·冈特表达我们诚挚的感谢，感谢他们多年来为公司所做的贡献。马蒂亚斯·海因策尔在掌管生命科学业务部门期间，成功重置了其战略和运营模式，组建了一支强大的高层领导团队，并使该业务走上了可持续增长的道路。

Under Peter Guenter’s leadership, our Healthcare business sector has set a clear strategic roadmap and delivered significant organic sales growth in every single quarter throughout his tenure as Healthcare CEO, coupled with achieving record EBITDA levels,” said Johannes Baillou, Chairman Executive Board and Family Board of E.

在彼得·吉恩特的领导下，我们的医疗保健业务部门制定了明确的战略路线图，在他担任医疗保健首席执行官期间，每个季度都实现了显著的有机销售增长，并达到了创纪录的息税折旧摊销前利润水平，”E公司执行董事会和家族董事会主席约翰内斯·巴伊洛表示。

Merck KG. “We warmly welcome Jean-Charles Wirth, Danny Bar-Zohar and Khadija Ben Hammada to the Executive Board of the company they already know so well. They bring deep expertise in their fields, strong leadership complemented by diverse backgrounds, international exposure and an innovative outlook that will further enrich our company.”.

默克公司表示：“我们热烈欢迎让-查尔斯·维尔特、丹尼·巴尔-佐哈尔和哈迪贾·本·哈马达加入他们已经非常熟悉的公司执行董事会。他们在各自领域拥有深厚的专业知识、强大的领导力，且背景多元、具有国际视野和创新思维，这将进一步丰富我们公司。”

“I join Mr. Baillou in extending my gratitude to Matthias Heinzel and Peter Guenter for their leadership and contribution at a very critical time in our journey. And I am delighted to welcome three proven internal leaders to join me on the Executive Board along with Kai Beckmann, CEO Electronics, and Helene von Roeder, Chief Financial Officer.

“我与贝鲁先生一同向马蒂亚斯·海因策尔和彼得·冈特表达感谢，感谢他们在我们旅程中一个非常关键的时刻所展现的领导才能和贡献。我非常高兴地欢迎三位经过验证的内部领导人加入执行董事会，他们将与电子部门首席执行官凯·贝克曼以及首席财务官海伦·冯·罗德一起共事。”

As a value compounder, Merck is focused on resilient growth, innovation, and people. The nomination of the next generation of leaders is testimony to the strong bench of global and diverse talents we have developed in recent years at Merck,” said Belén Garijo, Chair of the Executive Board and CEO of Merck.

默克公司作为一家价值复合型公司，专注于弹性增长、创新和人才。执行董事会主席兼默克公司首席执行官贝伦·加里奥表示：“下一代领导者的提名证明了近年来我们在默克培养的强大的全球多元化人才储备。”

“As One Merck, the Executive Board will remain sharply focused on securing long-term profitable growth across our three sectors.”.

“作为一个默克集团，执行董事会将继续专注于确保我们三个部门的长期盈利增长。”

Jean-Charles Wirth

让-查尔斯·维尔特

joined Merck in 2006 and is the Global Head of the Science and Lab Solutions business unit, which is the largest division within the Life Science business sector with more than €4 billion in sales. Prior to taking on that role in 2022, he held several roles of increasing responsibility in the company, including Head of Applied Solutions business unit, Chief Financial Officer for Life Science, where he played an active role in its transformation from a €2.3 billion to €6 billion solutions provider through a combination of organic growth, acquisitions, and strategic partnerships, and Head of Controlling for the Performance Materials sector (now Electronics).

于2006年加入默克公司，现任科学与实验室解决方案业务部门的全球负责人，该部门是生命科学业务领域中规模最大的分支，销售额超过40亿欧元。在2022年担任这一职务之前，他在公司内历任多个职责不断增加的职位，包括应用解决方案业务部门负责人、生命科学首席财务官，在此期间他通过有机增长、收购和战略合作伙伴关系，积极推动了该部门从23亿欧元到60亿欧元解决方案提供商的转型，还曾担任高性能材料部门（现为电子业务）的控制主管。

He has had oversight of multi-billion-euro P&Ls, and has led multinational teams from Operations, Commercialization and Business Development, always with a keen focus on customers’ needs. Prior to joining Merck, Jean-Charles Wirth worked for Baxter, Price Waterhouse Coopers and Alcatel Lucent. Jean-Charles Wirth is a global leader with deep expertise in finance, strategic planning, and a reputation for building energized, focused teams.

他负责监管数十亿欧元的损益表，并带领来自运营、商业化和业务发展的跨国团队，始终密切关注客户的需求。在加入默克之前，Jean-Charles Wirth 曾在百特、普华永道和阿尔卡特朗讯工作。Jean-Charles Wirth 是一位全球领导者，在财务和战略规划方面拥有深厚的专业知识，并以组建充满活力且专注的团队而闻名。

He is a global citizen who has worked and lived in France, Germany, and the United States, and has spent significant time in North Africa and Asia..

他是一位曾在法国、德国和美国工作和生活过的全球公民，并在北非和亚洲度过大量时间。

Danny Bar-Zohar

丹尼·巴尔-佐哈尔

has served as Global Head of Research & Development and Chief Medical Officer of the Healthcare business sector since 2022. In this capacity, he has been instrumental in transforming the R&D organization with a strong emphasis on creating a “drug-hunter mindset.” In addition to his oversight of R&D, he oversees External Innovation as well as Business Development for Healthcare.

自2022年起担任医疗保健业务领域的全球研发主管兼首席医学官。在此职位上，他在推动研发组织转型方面发挥了重要作用，特别强调培养“药物探索者思维”。除了负责研发工作外，他还负责医疗保健领域的外部创新和业务发展。

He joined the company in 2020 to serve as Global Head of Development. He has two decades of leadership experience in the pharmaceuticals sector, having worked previously at Novartis, Teva Pharmaceuticals and venture capital firm Syncona Investment Management. His experience includes global drug development from strategy to execution, across almost every modality in drug development, including small molecules, therapeutic proteins, antibodies and gene therapy.

他于2020年加入公司，担任全球开发主管。他在制药行业拥有二十年的领导经验，曾任职于诺华、梯瓦制药和风险投资公司Syncona Investment Management。他的经验涵盖从战略到执行的全球药物开发，涉及药物开发几乎所有领域，包括小分子、治疗蛋白、抗体和基因疗法。

His visionary approach to R&D has helped to deliver multiple new global therapeutic approvals at both Teva Pharmaceuticals and Novartis. Prior to joining the pharmaceutical industry, Danny Bar-Zohar spent several years training as a general surgeon at the Tel Aviv Sourasky Medical Center in Israel and served as an airborne rescue physician in the Israel Defense Forces (IDF)..

他对于研发的前瞻性方法帮助Teva制药和诺华公司获得了多个新的全球治疗批准。在加入制药行业之前，Danny Bar-Zohar曾在以色列特拉维夫苏拉斯基医疗中心接受多年普通外科医生培训，并在以色列国防军（IDF）担任过空中救援医生。

Khadija Ben Hammada

法蒂玛·本·哈马达

joined Merck in 2010 and has served as Chief Human Resources Officer since 2023. Since joining the company, she has held global roles in Europe, Asia-Pacific and the United States, driving transformations, major integrations and strategic initiatives across all sectors and various functions within Human Resources and beyond.

于2010年加入默克公司，并自2023年起担任首席人力资源官。自加入公司以来，她在欧洲、亚太和美国担任过全球职务，推动了各领域和人力资源及其他各个职能部门的转型、重大整合和战略举措。

She also held the role of Chief of Staff to the CEO of Merck, where she played a pivotal role in advancing a high-impact culture at Merck. Born in France, Khadija Ben Hammada has always valued learning and inclusion. She is a trailblazer in her field – representing the next generation of executives who lead with empathy and a people-first approach.

她还曾担任默克公司首席执行官的幕僚长，在推动默克高影响力文化的建设中发挥了关键作用。出生于法国的哈迪贾·本·哈马达一直重视学习和包容性。她是其领域的开拓者——代表着以同理心和以人为本方法领导的新一代高管。

As a business leader, Khadija Ben Hammada works towards a future where organizations succeed through a balanced combination of strategic leadership, sustainable practices, and a strong focus on people. Her vision is centered on fostering organizational excellence, employee upskilling, and guiding leadership development.

作为商界领袖，哈迪贾·本·哈马达致力于打造一个未来，让组织通过战略领导、可持续实践和高度关注员工的平衡组合取得成功。她的愿景聚焦于推动组织卓越、员工技能提升以及指导领导力发展。

During her tenure as Chief Human Resource Officer, her team has driven a portfolio of step-changes around leadership excellence and family-friendly benefit offerings such as enterprise-wide support for fertility and caregiving..

在其担任首席人力资源官期间，她的团队推动了一系列围绕领导力卓越和家庭友好型福利的变革，例如全公司范围内的生育和看护支持。

As of June 2025, the Executive Board of Merck will be structured as follows:

截至2025年6月，默克执行董事会的结构如下：

Belén Garijo, Chair of the Executive Board and CEO

贝伦·加里霍，执行董事会主席兼首席执行官

Board responsibility for Global Communications / Group Internal Auditing / Group Legal and Compliance / Group Political Office / Group Science & Technology Office / Group Strategy, M&A and Venturing

董事会负责全球通信/集团内部审计/集团法律与合规/集团政治办公室/集团科技办公室/集团战略、并购和风险投资

Danny Bar-Zohar, Member of the Executive Board

丹尼·巴尔-佐哈尔，执行董事会成员

CEO Healthcare and Board responsibility for Global Health & Health Equity

首席执行官医疗保健和董事会全球健康与健康公平责任

Kai Beckmann, Member of the Executive Board

贝克曼，执行董事会成员

CEO Electronics and Board responsibility for Patents & Scientific Information

首席执行官电子和董事会负责专利和科学信息

Khadija Ben Hammada, Member of the Executive Board

哈迪贾·本·哈马达，执行董事会成员

Chief People Officer and Board responsibility for Group Human Resources / Inhouse Consulting / Corporate Sustainability, Quality & Trade Compliance / Site Management at the company headquarters in Darmstadt, Germany

德国达姆施塔特公司总部的首席人力资源官和董事会负责集团人力资源/内部咨询/企业可持续发展、质量与贸易合规/场地管理职责

Helene von Roeder, Member of the Executive Board

海伦·冯·罗德尔，执行董事会成员

Chief Financial Officer and Board responsibility for Group Controlling / Group Financial Reporting / Group Procurement / Group Treasury / Group Tax / Investor Relations / Global Enterprise Solutions / Information Technology / Data & Digital

首席财务官和董事会负责集团控制/集团财务报告/集团采购/集团资金/集团税务/投资者关系/全球企业解决方案/信息技术/数据与数字化

Jean-Charles Wirth, Member of the Executive Board

让-查尔斯·维尔特，执行董事会成员

CEO Life Science

首席执行官 生命科学